Glaucoma Ocular hypertension Currently using original latanoprost Glaucoma Ocular hypertention Prostaglandins analogue Latanoprost Generic drug Intraocular pressure
Conditions
Interventions
Original latanoprost (Xalatan),Generic latanoprost 1 (Lanotan),Generic latanoprost 2 (Mylan)
Active Comparator Drug,Active Comparator Drug,Active Comparator Drug
Original,Generic 1,Generic 2
Sponsors
Bausch & Lomb Co., Ltd.
Atlanta Medicare Co.,
Ltd.
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients who have been diagnosed with any type of glaucoma or ocular hypertension No history of cataract within the last 3 months Using the original latanoprost (Xalatan) for more than 4 weeks
Exclusion criteria
Exclusion criteria: History of any type of intraocular pressure reduction surgery History of laser peripheral iridotomy within the last 3 months History of ocular trauma Currently on more than 1 antihypertensive eyedrops apart from latanoprost History of any irregular ocular surface condition Currently on glucocorticoid eyedrops
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraocular pressure reduction at 4 and 12 week after start the intervention Goldmann applanation tonometer | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety at 4 and 12 week after start the intervention Physical examination, patients' comment | — |
Contacts
Public ContactNuntachai Surawatsatien
King Chulalongkorn Memorial Hospital
Outcome results
None listed